期刊
BMC CANCER
卷 23, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s12885-023-11237-y
关键词
Renal cell carcinoma; Tyrosine kinase inhibitors; Immunotherapy; Consensus; Cabozantinib
类别
In advanced Renal Cell Carcinoma (aRCC), systemic therapy with TKIs and IOs is recommended, as surgery has little role in these patients. The sequencing of therapies is crucial in determining subsequent line therapy. However, in India, there are barriers to RCC treatment, including the high cost of immunotherapy and the consideration of disease burden in treatment decision-making. The lack of India-specific guidelines for ccRCC treatment and sequencing further complicates management. This consensus article provides valuable expert recommendations based on clinical evidence for specialists treating advanced ccRCC.
In advanced Renal Cell Carcinoma (aRCC), systemic therapy is the mainstay of treatment, with no or little role for surgery in these patients. Tyrosine kinase inhibitors (TKIs) and immune-oncological (IOs) therapies, either alone or in combination, are recommended in these patients depending on patient and tumour factors. The sequencing of therapies is critical in RCC because the choice of subsequent line therapy is heavily dependent on the response and duration of the previous treatment. There are additional barriers to RCC treatment in India. Immunotherapy is the cornerstone of treatment in ccRCC, but it is prohibitively expensive and not always reimbursed, effectively putting it out of reach for the vast majority of eligible patients in India. Furthermore, in advanced RCC (particularly the clear cell variety), Indian oncologists consider the disease burden of the patients, which is particularly dependent on the quantum of the disease load, clinical symptoms, and performance status of the patient, before deciding on treatment. There are no India-specific guidelines for clear cell RCC (ccRCC) treatment or the positioning and sequencing of molecules in the management of advanced ccRCC that take these country-specific issues into account. The current consensus article provides expert recommendations and treatment algorithms based on existing clinical evidence, which will be useful to specialists managing advanced ccRCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据